Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.13 USD | -0.88% | -8.13% | -36.52% |
May. 10 | Transcript : Protalix BioTherapeutics, Inc., Q1 2024 Earnings Call, May 10, 2024 | |
May. 10 | Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | 52.7M | Sales 2025 * | 101M | Capitalization | 82.85M |
---|---|---|---|---|---|
Net income 2024 * | 8M | Net income 2025 * | 54M | EV / Sales 2024 * | 1.57 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.82 x |
P/E ratio 2024 * |
9.42
x | P/E ratio 2025 * |
1.79
x | Employees | 208 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.42% |
Latest transcript on Protalix BioTherapeutics, Inc.
1 day | -0.88% | ||
1 week | -8.13% | ||
1 month | -0.88% | ||
3 months | -30.67% | ||
6 months | -25.17% | ||
Current year | -36.52% |
Managers | Title | Age | Since |
---|---|---|---|
Dror Bashan
CEO | Chief Executive Officer | 57 | 19-06-29 |
Eyal Rubin
DFI | Director of Finance/CFO | 48 | 19-07-21 |
Yael Hayon
CTO | Chief Tech/Sci/R&D Officer | 41 | 20-07-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Pol Boudes
BRD | Director/Board Member | 67 | 19-11-30 |
Gwen Melincoff
BRD | Director/Board Member | 72 | 19-11-30 |
Aharon Schwartz
BRD | Director/Board Member | 80 | 14-10-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +3.86% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 1.13 | -0.88% | 345,304 |
24-05-30 | 1.14 | +1.79% | 280,197 |
24-05-29 | 1.12 | -3.45% | 317,587 |
24-05-28 | 1.16 | -5.69% | 499,105 |
24-05-24 | 1.23 | +4.24% | 302,947 |
Delayed Quote Nyse, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.52% | 82.85M | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+0.04% | 12.16B | |
+25.12% | 12.21B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- PLX Stock